Cullinan Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

CGEM$11.23-4.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Preferred Stock · Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · Total Stockholders'
	Shares	Amount	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balances at December 31, 2025	555,935	$—	60,244,136	$6	$995,823	$1,020	$(588,119)	$408,730
Conversion of preferred stock into common stock	(73,946)	—	739,460	—	—	—	—	—
Issuance of common stock under equity-based compensation plans	—	—	467,784	—	380	—	—	380
Equity-based compensation	—	—	—	—	7,616	—	—	7,616
Unrealized loss on investments	—	—	—	—	—	(893)	—	(893)
Net loss	—	—	—	—	—	—	(49,661)	(49,661)
Balances at March 31, 2026	481,989	—	61,451,380	6	1,003,819	127	(637,780)	366,172
Issuance of common stock under equity-based compensation plans	—	—	116,590	—	1,100	—	—	1,100
Conversion of preferred stock into common stock	(277,780)	—	2,777,800	—	—	—	—	—
Equity-based compensation	—	—	—	—	8,447	—	—	8,447
Unrealized loss on investments	—	—	—	—	—	(261)	—	(261)
Net loss	—	—	—	—	—	—	(53,704)	(53,704)
Balances at June 30, 2026	204,209	—	64,345,770	6	1,013,366	(134)	(691,484)	321,754
Issuance of common stock under equity-based compensation plans	—	—	124,004	—	1,062	—	—	1,062
Conversion of preferred stock into common stock	(43,115)	—	431,150	—	—	—	—	—
Equity-based compensation	—	—	—	—	8,374	—	—	8,374
Unrealized loss on investments	—	—	—	—	—	(518)	—	(518)
Net loss	—	—	—	—	—	—	(49,388)	(49,388)
Balances at September 30, 2026	161,094	$—	64,900,924	$6	$1,022,802	$(652)	$(740,872)	$281,284

Preferred Stock · Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · Total Stockholders'
	Shares	Amount	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balances at December 31, 2024	647,500	$—	58,510,610	$6	$958,695	$(133)	$(368,240)	$590,328
Issuance of common stock under equity-based compensation plans	—	—	188,309	—	—	—	—	—
Equity-based compensation	—	—	—	—	9,374	—	—	9,374
Unrealized gain on investments	—	—	—	—	—	638	—	638
Net loss	—	—	—	—	—	—	(48,501)	(48,501)
Balances at March 31, 2025	647,500	—	58,698,919	6	968,069	505	(416,741)	551,839
Issuance of common stock under equity-based compensation plans	—	—	59,724	—	373	—	—	373
Issuance of common stock upon exercise of pre-funded warrants	—	—	315,748	—	—	—	—	—
Equity-based compensation	—	—	—	—	9,887	—	—	9,887
Unrealized gain on investments	—	—	—	—	—	102	—	102
Net loss	—	—	—	—	—	—	(70,055)	(70,055)
Balances at June 30, 2025	647,500	—	59,074,391	6	978,329	607	(486,796)	492,146
Issuance of common stock under equity-based compensation plans	—	—	1,868	—	—	—	—	—
Equity-based compensation	—	—	—	—	9,467	—	—	9,467
Unrealized gain on investments	—	—	—	—	—	366	—	366
Net loss	—	—	—	—	—	—	(50,610)	(50,610)
Balances at September 30, 2025	647,500	$—	59,076,259	$6	$987,796	$973	$(537,406)	$451,369

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.